| Theme | Tumors and bone mineral metabolism | |
|---|---|---|
| Title | Bone-modifying agents for breast cancer patients receiving hormonal therapy | |
| Publish Date | 2014/01 | |
| Author | Atsushi Shimomura | Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine |
| Author | Shinzaburo Noguchi | Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine |
| [ Summary ] | Use of aromatase inhibitors for postmenopausal breast cancer patients induces a reduction of estrogen levels and a subsequent loss of bone mineral density, resulting in an increased rate of bone fracture. Bone-modifying agents, such as bisphosphonates and denosumab, have been shown to prevent the loss of bone mineral density in patients treated with aromatase inhibitors. | |